Key Points
Chip maker Nvidia (NASDAQ: NVDA) and pharmaceutical company Eli Lilly (NYSE: LLY) are collaborating to build a joint research lab, announced during the JPMorgan Healthcare Conference in January. The companies will invest up to $1 billion over the next five years to construct, staff, and equip the facility, which will utilize Nvidia’s latest AI processors, the Vera Rubin chips, to enhance drug discovery.
This partnership aims to merge Eli Lilly’s extensive data and scientific expertise with Nvidia’s computational power, creating a more efficient drug development process. Both companies have indicated that this could significantly accelerate traditional drug discovery, which has historically been lengthy and expensive.
The research lab represents a strategic pivot for Nvidia, further integrating its technology within the healthcare sector while positioning Eli Lilly to leverage cutting-edge AI in its R&D efforts. This collaboration is poised to redefine the future of drug discovery.
